Essential Tremor Pipeline Report 2025: Breakthrough Therapies and Emerging Players

Strategic Insights -

As of October 20, 2025, DelveInsight's comprehensive Essential Tremor Pipeline Insight report highlights the dynamic pipeline landscape, featuring 7+ companies and 10+ pipeline drugs being developed for the treatment of essential tremor. The report provides an in-depth analysis of the pipeline therapies, including their mechanism of action, clinical trials, and emerging players.

The report sheds light on the safety and efficacy of JZP385 in moderate to severe ET, conducted by Jazz Pharmaceuticals in July 2025. DelveInsight's Essential Tremor Pipeline report showcases a robust space with 7+ active players working on 10+ pipeline therapies for ET treatment. Promising therapies like SAGE-324, CAD-1883, NBI-827104, JZP385, CX-8998, SAGE-217, Memantine, and Pregabalin are being developed by leading companies such as Merz Pharma, SAGE Therapeutics, GE Healthcare, Praxis Precision Medicines, OB Pharmaceuticals, Novartis, Jazz Pharmaceuticals, and others.

Key Takeaways:

  • Jazz Pharmaceuticals conducted a study of the safety and efficacy of JZP385 in moderate to severe ET in July 2025.
  • DelveInsight's Essential Tremor Pipeline report depicts a robust space with 7+ active players working on 10+ pipeline therapies for ET treatment.
  • Promising Essential Tremor Therapies include SAGE-324, CAD-1883, NBI-827104, JZP385, CX-8998, SAGE-217, Memantine, Pregabalin, and others.
  • Leading Essential Tremor Companies are Merz Pharma, SAGE Therapeutics, GE Healthcare, Praxis Precision Medicines, OB Pharmaceuticals, Novartis, Jazz Pharmaceuticals, and others.

Statistics:

  • 7+ active companies are working on Essential Tremor pipeline therapies.
  • 10+ pipeline drugs are being developed for Essential Tremor treatment.
  • 3+ clinical trials are being conducted for Essential Tremor pipeline therapies.
  • 7+ emerging Essential Tremor therapies are being developed by innovative companies.

Sources:

  • M2 PRESSWIRE - October 20, 2025 - Essential Tremor Pipeline Drugs Report 2025 highlights MOA, Emerging Therapies, Clinical Trials | DelveInsight.
  • DelveInsight's Essential Tremor Pipeline Insight 2025 report.